S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind

Anebulo Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANEB)

$2.36
-0.01 (-0.42%)
(As of 12/4/2023 ET)
Compare
Today's Range
$2.11
$2.44
50-Day Range
$1.71
$3.27
52-Week Range
$1.62
$4.05
Volume
5,750 shs
Average Volume
9,514 shs
Market Capitalization
$60.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Anebulo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
182.5% Upside
$6.67 Price Target
Short Interest
Healthy
0.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.29mentions of Anebulo Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

379th out of 952 stocks

Pharmaceutical Preparations Industry

169th out of 434 stocks


ANEB stock logo

About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

ANEB Stock Price History

ANEB Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Anebulo Pharmaceuticals Announces New CEO
H.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)
Anebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. Wainwright
See More Headlines
Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/20/2023
Today
12/04/2023
Next Earnings (Estimated)
2/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANEB
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+182.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-11,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.41 per share

Miscellaneous

Free Float
3,614,000
Market Cap
$60.49 million
Optionable
Not Optionable
Beta
-1.14
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Joseph F. Lawler M.D. (Age 51)
    Ph.D., Founder & Chairman
    Comp: $11k
  • Dr. Kenneth C. Cundy Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $425.15k
  • Mr. Richard Anthony Cunningham (Age 52)
    CEO & Director
  • Mr. Daniel V. George (Age 53)
    Principal Accounting Officer, Acting CFO & Secretary
  • Mr. Scott L. Anderson
    Head of Investor Relations & Public Affairs














ANEB Stock Analysis - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings
or view top-rated stocks.

What is Anebulo Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12 month price targets for Anebulo Pharmaceuticals' shares. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 182.5% from the stock's current price.
View analysts price targets for ANEB
or view top-rated stocks among Wall Street analysts.

How have ANEB shares performed in 2023?

Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 2.6% and is now trading at $2.36.
View the best growth stocks for 2023 here
.

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short.
View Anebulo Pharmaceuticals' Short Interest
.

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 9th 2024.
View our ANEB earnings forecast
.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Wednesday, September, 20th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10).

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

Who are Anebulo Pharmaceuticals' major shareholders?

Anebulo Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.08%).
View institutional ownership trends
.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANEB) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -